---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000118"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-09-28T23:59:59+00:00"
generated_at: "2026-06-23T07:01:16.702384+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data

## Summary
- IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.
- Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023.
- Cash runway guidance into calendar year 2025 remains unchanged, including Phase 1 costs for IMVT-1402.
- Composition of matter patent protection expected for IMVT-1402 through at least 2042.
- Batoclimab programs in Myasthenia Gravis, Thyroid Eye Disease, CIDP and Graves' Disease continue at full speed.

## SEC filing metadata
- accession: 0001764013-22-000118
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000118/0001764013-22-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000118/imvt-20220928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000118
- JSON: https://secwatch.observer/filing/0001764013-22-000118.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.